Platinum ppinion counterview: the evidence base for the benefit of magnetic resonance imaging-directed prostate cancer diagnosis is sound

We read with interest the Platinum Opinion by Vickers et al [1] suggesting that the routine use of magnetic resonance imaging (MRI) for early detection of prostate cancer in patients with elevated serum prostate-specific antigen levels, as advised by the urological guidelines, are misguided and not justified by clinical trials evidence. Their arguments focus on the lack of oncological equivalence of cancers found via MRI-directed biopsies (MRDBs) against systematic 10–12-core biopsies (SBs). Furthermore, they comment on the lack of superiority of MRI approaches for detection of higher-grade (grade group [GG] ≥2) cancers.